Synvitta Diagnostics announces bold mission to advance multiplex diagnostic testing
Press release from Synvitta Diagnostics
ALACHUA, Fla. – Synvitta Diagnostics, Inc., a biotechnology company developing next-generation diagnostic solutions, today announced a strategic partnership between Mitch Glaeser, Co-Founder and Chief Executive Officer, and Rainara Almeida, M.Sc., Co-Founder and Chief Scientific Officer. This partnership combines experienced business leadership along with deep scientific expertise to accelerate the development and commercialization of Synvitta’s proprietary diagnostic platform.
Synvitta Diagnostics is focused on transforming diagnostic workflows through high-performance, accessible technologies, including both rapid singleplex assays and a scalable multiplex platform designed to enable simultaneous detection of multiple biomarkers in a single test.
Mitch Glaeser, a seasoned entrepreneur and business leader, will lead strategic growth, partnerships, and commercialization efforts. “Synvitta represents a powerful combination of innovation and entrepreneurship,” said Mitch Glaeser, Co-Founder and CEO. “The ability to deliver multiplex diagnostics in a simple and scalable format creates a significant opportunity across multiple areas of healthcare.”
Synvitta’s technology is designed to integrate seamlessly into existing laboratory workflows, reducing operational complexity while maintaining high sensitivity and reliability.
“Our mission is to make diagnostics more precise, faster, and accessible,” said Rainara Almeida, M.Sc., Co-Founder and CSO of Synvitta Diagnostics. “We are building a platform that simplifies complex testing while maintaining high analytical performance, enabling better and faster clinical decision-making.”
Looking ahead, the company is expanding its platform to support a broad pipeline of diagnostic solutions, including infectious diseases, autoimmune conditions, and neurodegenerative disorders, leveraging its multiplex capabilities to address critical unmet needs in healthcare.
Operating from UF Innovate | Sid Martin Biotech, one of the leading biotech incubators in the world, Synvitta is actively advancing its product pipeline and engaging with clinical and strategic partners in the U.S. and internationally.